98%
921
2 minutes
20
Computational modelling has gained attention for evaluating nanoparticle-based drug delivery systems. Physiologically based pharmacokinetic (PBPK) modelling provides a mechanistic approach for evaluating drug biodistribution. The aim of this work is to develop a specific PBPK model to simulate stavudine biodistribution after the administration of a 40 nm gold nanoparticle-based drug delivery system in rats. The model parameters used have been obtained from literature, in vitro and in vivo studies, and computer optimization. Based on these, the PBPK model was built, and the compartments included were considered as permeability rate-limited tissues. In comparison with stavudine solution, a higher biodistribution of stavudine into HIV reservoirs and the modification of pharmacokinetic parameters such as the mean residence time (MRT) have been observed. These changes are particularly noteworthy in the liver, which presents a higher partition coefficient (from 0.27 to 0.55) and higher MRT (from 1.28 to 5.67 h). Simulated stavudine concentrations successfully describe these changes in the in vivo study results. The average fold error of predicted concentrations after the administration of stavudine-gold nanoparticles was within the 0.5-2-fold error in all of the tissues. Thus, this PBPK model approach may help with the pre-clinical extrapolation to other administration routes or the species of stavudine gold nanoparticles.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875329 | PMC |
http://dx.doi.org/10.3390/pharmaceutics14020406 | DOI Listing |
AAPS J
September 2025
Clinical Pharmacology Laboratory, Clinical Center, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 5A03, Bethesda, Maryland, 20892, USA.
Antibody-drug conjugates (ADCs) represent a rapidly expanding class of therapeutics, uniquely combining the specificity of monoclonal antibodies with the potency of cytotoxic small-molecule payloads. Due to their inherent structural complexity and heterogeneous composition, accurate characterization and quantification of ADCs pose significant bioanalytical challenges. This review discusses recent advancements in bioanalytical methodologies, including ligand binding assays (LBAs), liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based approaches, and emerging hybrid LBA-LC-MS/MS platforms.
View Article and Find Full Text PDFJ Pharmacokinet Pharmacodyn
September 2025
Centre for Applied Pharmacokinetic Research (CAPKR), University of Manchester, Manchester, UK.
Concentration-dependent binding to red blood cells is a characteristic of several drugs, complicating the understanding of how pathophysiological factors influence drug behavior. This study utilized user-friendly, physiologically-based pharmacokinetic (PBPK) models to compare concentration-dependent and independent blood-to-plasma drug concentration ratios (B/P), using tacrolimus as a case study. Two models were developed and validated for tacrolimus using clinical data from healthy volunteers; Model 1 accounted for saturable blood binding, and Model 2 used a constant B/P level.
View Article and Find Full Text PDFAAPS J
September 2025
Pharmaceutical Science, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut, 06340, USA.
A virtual bioequivalence (VBE) approach utilizing physiologically based pharmacokinetic (PBPK) modeling presents a compelling alternative for pharmaceutical industries. This method can significantly reduce the time and cost associated with clinical bioequivalence (BE) trials while minimizing the risk of detecting a type II error (a false negative), as well as a type I error (a false positive). Additionally, it aligns with ethical considerations by obviating the need to expose healthy volunteers to investigational drugs.
View Article and Find Full Text PDFAAPS J
September 2025
Certara Predictive Technologies, Certara, Sheffield, UK.
In vitro permeation testing (IVPT) is commonly used to assess dermal drug delivery, yet its utility can be challenged by high variability and the need for large sample sizes to achieve sufficient statistical power. Dermal physiologically based pharmacokinetic (PBPK) models provide a mechanistic approach to better interpret IVPT results and to extrapolate in vitro to in vivo. In the present work, a dermal PBPK model for caffeine was developed using a bottom-up approach with minimal parameter optimization.
View Article and Find Full Text PDFBiol Pharm Bull
August 2025
Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan.
The broad-spectrum antifungal agent voriconazole elicits different responses. Polymorphisms in cytochrome P450 (P450) 2C19 may partially explain this variability. This study generated virtual plasma/hepatic exposures to voriconazole in Japanese P450 2C19 poor metabolizers using both simplified and population-based full physiologically based pharmacokinetic (PBPK) modeling systems.
View Article and Find Full Text PDF